NORD.US Nordicus Partners Corporation Common Stock

Healthcare Diversified Consumer Services USA Stocks
2.51 USD
Close of Nov 14, 2026
1.48 5.15
Market cap
USD 48.8M
P/E
-
P/B
0.79x
ROE
-6.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Aug 2026.

Is NORD.US undervalued?

Graham number

The Graham number of Nordicus Partners Corporation Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nordicus Partners Corporation Common Stock fundamental analysis

No fundamental analysis for Nordicus Partners Corporation Common Stock yet.

Nordicus Partners Corporation Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nordicus Partners Corporation Common Stock

Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.

Full company profile